Thaum Lub Ib Hlis 29, 2025, pab pawg tshawb fawb Suav tau tshaj tawm ib tsab xov xwm hu ua "Neoadjuvant pyrotinib thiab trastuzumab hauv HER2 zoo mob qog noj ntshav mis tsis muaj kev teb thaum ntxov (NeoPaTHer): kev ua haujlwm zoo, kev nyab xeeb, thiab kev tshuaj xyuas biomarker ntawm kev tshawb fawb yav tom ntej, ntau lub chaw, kev teb hloov kho" hauv phau ntawv xov xwm "Signal Transduction thiab Targeted Therapy".
Kab mob qog noj ntshav hauv lub mis uas muaj tus kab mob hu ua Human epidermal growth factor receptor 2 (HER2)-positive, uas yog li ntawm 15% txog 25% ntawm tag nrho cov kab mob qog noj ntshav hauv lub mis, yog ib hom kab mob uas txawv thiab ua rau neeg mob hnyav. Nws yog ib hom kab mob uas muaj HER2 ntau dhau, ib hom transmembrane receptor tyrosine kinase uas pab kom cov qe ntshav dawb loj hlob thiab muaj sia nyob. Cov neeg mob uas muaj kab mob qog noj ntshav hauv lub mis uas muaj HER2-positive muaj feem yuav rov qab mob dua thiab tuag ntau dua piv rau cov neeg uas muaj lwm hom kab mob qog noj ntshav hauv lub mis, ua rau nws yog ib hom kab mob uas nyuaj kho heev. Txawm li cas los xij, kev kho mob qog noj ntshav hauv lub mis uas muaj HER2-positive tau hloov pauv ntau heev hauv ob xyoo dhau los, feem ntau yog vim muaj kev qhia txog kev kho mob uas tsom mus rau HER2. Tshwj xeeb, kev siv trastuzumab tau hloov pauv txoj kev kho mob qog noj ntshav hauv lub mis uas muaj HER2-positive los ntawm ib hom kab mob uas ua rau neeg tuag taus mus rau ib hom uas yooj yim tswj thiab tsis tshua muaj teeb meem.
Nruab nrab ntawm lub Kaum Hli Ntuj xyoo 2020 thiab lub Peb Hlis Ntuj xyoo 2022, tag nrho muaj 129 tus neeg mob los ntawm tsib lub tsev kho mob tau sau npe rau hauv txoj kev tshawb fawb no. Ntawm 129 tus neeg mob uas tau sau npe, 62 (48.1%) tau txheeb xyuas tias yog cov neeg teb MRI (pawg A), 26 tus neeg tsis teb txuas ntxiv nrog plaub lub voj voog ntxiv ntawm TCbH (pawg B), thiab 41 tus neeg tsis teb tau txais pyrotinib ntxiv (pawg C). Tus nqi tpCR yog 30.6% (95% CI: 20.6–43.0%) hauv pawg A, 15.4% (95% CI: 6.2–33.5%) hauv pawg B, thiab 29.3% (95% CI: 17.6–44.5%) hauv pawg C. Kev tshuaj xyuas ntau yam logistic regression tau qhia txog qhov sib piv ntawm kev ua tiav tpCR ntawm pawg A thiab C (qhov sib piv = 1.04, 95% CI: 0.40–2.70). Tsis muaj cov xwm txheej tsis zoo tshiab tau pom nrog kev ntxiv ntawm pyrotinib. Cov neeg mob uas muaj kev hloov pauv ntawm TP53 thiab PIK3CA tau pom tias muaj cov lus teb qeeb dua piv rau cov neeg tsis muaj lossis muaj kev hloov pauv ntawm ib qho gene (36.0% vs. 60.0%, P = 0.08). Cov kev tshawb pom no qhia tias kev ntxiv pyrotinib yuav pab tau cov neeg mob uas tsis teb rau neoadjuvant trastuzumab ntxiv rau chemotherapy. Yuav tsum tshawb nrhiav ntxiv kom paub cov cim qhia txog cov neeg mob uas yuav tau txais txiaj ntsig los ntawm kev ntxiv pyrotinib.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
Email：myimmnet@163.com
Cov ntaub ntawv siv los ua piv txwv
https://www.nature.com/articles/s41392-025-02138-6
Lub sijhawm tshaj tawm: Lub Ob Hlis-08-2025